Theratechnologies Inc T.TH

Cost of Lutathera in Canada

[jfm1330]

I found a pricing reference for Lutathera in Canada. It also includes the pricing for Sandostatin LAR, a peptide drug, and also the cost of chemotherapy drugs for neuroendocrine cancers. The cost of Lutathera is 140,000$ CAN for four cycles, so 35,000$ per dose. Initiation of treatment is four cycles every two months, maybe more if they see good tumor regression. If it's only stable disease, they will treat again when they will see cancer progression again.

The cost of Sandostatin LAR (Octreotide LAR 60 mg) is 4000$ CAN per dose, with a dose every four weeks, so 52,000$ per year only for a long acting release formulation of the peptide. So it gives a good idea of the pricing TH1902 and other PDCs derived from TH19P01 could achieve. I did not find the pricing in the US, but it is surely higher by a good margin.

So imagine the pricing for a PDC like TH1902 with treatment cycles of three weeks, instead of two months. You could end up maybe with 10 to 20 cycles of treatment given the expected wider therapeutic window. Obviously, it needs to be efficaciuous.

https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_inEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf

[Wino115]

This is a key point for their potential profitability. While PL and Marsolais always state the characteristics around TH1902 may be a new paradigm for the way you treat cancer, PL and Dubuc need to start highlighting that this also, by definition, means it could lead to a new financial model paradigm as a result. The characteristic of possibly longer patient treatment periods and more frequent

[jfm1330]

It's too early for them to talk about that. They need efficacy data first. But if TH1902 shows good efficacy, then it will be the time to push that forward.

[scarlet1967]

I absolutely agree with you, point is there not many comps. We can look at some ADC drugs but again although a targeted drug delivery they are more expensive to manufacture and have some clinical disadvantages which should translate to less commerciality compared to an approved PDC. They really need to start educating the market re their financials of their PDC if and when approved. Again bicycle

[jeffm34]

There is a report available that may given an indication of potential market size for TH1902.  It cost $4000 though.  https://www.360marketupdates.com/global-docetaxel-market-13717105

[scarlet1967]

No company big or small would start a multi billion project unless they have done a proforma full analysis in advance. It's not only the size of the targeted market, drug pricing, competitions, agencies' policies, insurers's policies and of course thei strength of their science and probability of success and cost of the trial but all of it. So they have already an internal report so

[jeffm34]

No company is going to release their internal analysis publicly. The best investors can hope for is to get an idea of the potential market size for TH1902. A good starting point to estimate that is sales of docetaxel broken down by cancer type.  I haven't been able to find that other than paying $4000 for a report.  If you have that info please share as it would be helpful for

[scarlet1967]

There are many reports re PDC market about, some even mentioning THTX all need to be purchased and quite frankly those research companies behind the reports to me don't look legit. I didn't want them to release the full analysis but the part which had to do with financial opportunities of the drug which is the reason they committed themselves to the project. Point is if those returns are

[SPCEO1]

It is worth remembering that PL said earlier this year, before they added more tumors to their list that the addressable market was $12 billion. That is the revenues currently earned in the cancer markets they would hope to be in. So, just a starting point. But they have been thinking about this since early this year at least.

[jfm1330]

I just found an incredibly good comparator to Thera in oncology. In a sense it seems positive, but in another it's negative. I still need to read about it, but it's a company that is where Thera could be in one or two years. One thing is sure, this will be a competitor and the company to beat, but on the other hand, it provides some validation in the field of enhancing generic cancer drugs

[scarlet1967]

I hope he does mention those numbers more often ,a breakdown would be even better. I spend some time today looking into current ADC's try to finalize it tomorrow. ADC's have the advantage of being around for almost a decade and multiple companies are currently commercializing their drug and have been doing it for a while. They are not the perfect comps but target delivery drugs chasing

[qwerty22]

I think you're all being too prescriptive with comparables. Hopefully we get some expert comment on what is a good comparable. I get there are molecular and mechanistic differences between ADCs and PDCs but there is so much more in common that they work. It's really too early to talk about indication comparables because I see that change, possibly dramatically, with data. Maybe you can go

[Wino115]

I would also like to eventually hear from some practicing KOLs as to the possible usage of a drug like TH1902 assuming success in the trial.  We may be surprised at how "users" of these drugs position the pros and cons of each and how they'd used them. isn't it more a question of how the characteristics of TH1902 work within the disease progression and patient history and

[qwerty22]

It's not too generalized. It seems to me exactly how analysts look at this once you have a clearer picture of the drugs profile. It's even more than just the pre-existing drugs. They are competing for attention with upcoming techs like bi-specific antibodies, off-the-shelf CAR T etc. Some of these have a lot of heat in them and we'll see how some results in those tech begin to play out